InsidersTradesSigma
MAAT PHARMA Stock: price and directors' dealings · France · AMF
Track the MAAT PHARMA stock price and the full management transaction log of the company, a publicly traded company based in France. Shares are listed on FR FR, under the supervision of AMF. Operating in the Healthcare & Pharma sector, MAAT PHARMA has logged 59 public disclosures. Market capitalisation: €54.3m. The latest transaction was reported on 29 May 2026 (Acquisition). Among the most active insiders: SEVENTURE PARTNERS SOCIETE ANONYME A DIRECTOIRE. Every trade is accessible without an account.
59
Insider Decl.
0
Thresholds
€1m
13 ops.
Buy Volume
€3m
38 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate MAAT PHARMA Buy (bullish), based on 2 analysts. Average price target: €6.50.
50Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 May 2026
Declarations59 total
2,000 shares@ €2.790.010% mcap3.5% of flowActionEuronext Paris2026DD1117103
Ideal exit: 22 Feb 2027 (T+270)
25,423 shares@ €6.1112.2% of flowActionEuronext Paris2026DD1091318
57,964 shares@ €6.0627.6% of flowActionEuronext Paris2026DD1091222
19,624 shares@ €5.08277.8% of flowActionEuronext Paris2026DD1088776
24,304 shares@ €5.388110.3% of flowActionEuronext Paris2026DD1088355
81,190 shares@ €5.398634.5% of flowActionEuronext Paris2026DD1088050
16,895 shares@ €5.15786.9% of flowActionEuronext Paris2026DD1087751
2,600 shares@ €3.485.8% of flowActionEuronext Paris2025DD1071415
Ideal exit: 15 Aug 2026 (T+270)
430 shares@ €3.481.0% of flowActionEuronext Paris2025DD1070840
Ideal exit: 15 Aug 2026 (T+270)
431,034 shares@ €3.486.4% of flowActionHors plateforme de négociation2025DD1070137
819,672 shares@ €6.1021.2% of flowActionEuronext Paris2025DD1028072
104 shares@ €8.0160.0% of flowActionEuronext Paris2025DD1018335
46 shares@ €8.10170.0% of flowActionEuronext Paris2025DD1018054
515 shares@ €8.02630.2% of flowActionEuronext Paris2025DD1017875
407 shares@ €8.01460.1% of flowActionEuronext Paris2025DD1017413
398 shares@ €8.02920.1% of flowActionEuronext Paris2025DD1017136
361 shares@ €8.18850.1% of flowActionEuronext Paris2025DD1016915
1,278 shares@ €8.31520.4% of flowActionEuronext Paris2025DD1016732
367 shares@ €8.33040.1% of flowActionEuronext Paris2025DD1016734
1,599 shares@ €8.16530.5% of flowActionEuronext Paris2025DD1016429
946 shares@ €8.01320.3% of flowActionEuronext Paris2025DD1016076
542 shares@ €8.01170.2% of flowActionEuronext Paris2025DD1015907
550 shares@ €8.06110.2% of flowActionEuronext Paris2025DD1015693
12,564 shares@ €8.03163.7% of flowActionEuronext Paris2025DD1015398
404 shares@ €8.07290.1% of flowActionEuronext Paris2025DD1015307
25 of 59 declarations
About MAAT PHARMA
MaaT Pharma is a French clinical-stage biotechnology company listed on Euronext Paris under the ticker MAAT and ISIN FR0012634822. Built around a highly specialized scientific expertise in the microbiome, the company focuses on microbiome-based biotherapies and aims to improve survival outcomes for cancer patients through immune modulation. MaaT Pharma was listed on November 8, 2021, a milestone that enhanced its market visibility and financing capacity. The company’s core platform is its proprietary Microbiome Ecosystem Therapies™ (MET) approach, designed to restore gut microbiome balance and support immune response. Its business is centered on clinical development rather than broad commercial sales, with a strong focus on high-unmet-need oncology and hematology settings. Its lead asset, Xervyteg® (MaaT013), has been developed for severe indications in medically fragile patients, while MaaT033 is currently being evaluated in a potentially pivotal Phase 2b trial. This clinical pipeline reflects a strategy built around scientifically differentiated, value-creating milestones. MaaT Pharma has established a niche position at the intersection of microbiology, immunology and oncology. It stands out as one of the few European listed companies pursuing microbiome-derived therapies for cancer-related complications, in an emerging market that remains early but structurally attractive. A key operational achievement was the completion, with Skyepharma, of what the company described as Europe’s largest manufacturing facility dedicated to Microbiome Ecosystem Therapies. This manufacturing footprint supports both clinical supply and the potential transition toward commercialization. Geographically, MaaT Pharma is headquartered in France but has an international operating profile. Its clinical development, partnerships and regulatory interactions are largely Europe-oriented, while the commercial strategy is being prepared for broader market access. In 2025, the company signed an exclusive license and distribution agreement with Clinigen to support European patient access to Xervyteg® if marketing authorization is obtained, highlighting the company’s step-by-step commercialization model. MaaT Pharma is also followed by several analysts and is widely viewed as a reference French biotech name, with its investment case driven by clinical execution, regulatory progress and financing milestones.
